gilteritinib (Xospata)

Indications

• acute myeloid leukemia (AML), FLT3 mutation positive
  • for use in combination with standard cytarabine & daunorubicin induction & cytarabine consolidation

Dosage

• 80 mg PO QD (40-120 mg) on days 4-17 of each 28 day cycle

Adverse effects

• febrile neutropenia 65.3%
• thrombocytopenia 20.4%

• drug adverse effects of tyrosine kinase inhibitor(s)

Mechanism of action

• inhibits FLT3 receptor tyrosine kinase
• also inhibits anaplastic lymphoma kinase (ALK, CD246)

More general terms

• antineoplastic agent (chemotherapeutic agent)
• tyrosine kinase inhibitor

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=49803313
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=76970819